静脉胰岛素与葡萄糖输注同重症监护病房及住院病死率的相关性:一项回顾性研究
该回顾性关联研究纳入2012年1月至2017年9月间一所内科-外科ICU收治的成人患者,排除入住<24 h、糖尿病酮症酸中毒、入住时限制治疗及再入院者。最终3966例纳入分析,采用多因素logistic回归评估静脉胰岛素和葡萄糖输注与ICU及住院病死率的关系。结果显示,入住>24 h患者中,静脉胰岛素每增加0.1 IU/kg与ICU病死率(OR 1.09,95%CI 1.05-1.13)和住院病死率(OR 1.09,95%CI 1.06-1.13)相关;静脉葡萄糖每增加1 g/d与ICU病死率相关(OR 1.01,95%CI 1.00-1.01),与住院病死率无显著相关(OR 1.00,95%CI 1.00-1.01)。入住>72 h亚组(n=1550)中,胰岛素剂量与ICU病死率(p=0.002)和住院病死率(p<0.001)相关,葡萄糖输注则无显著相关(p=0.08和p=0.2)。作者认为,该相关性可能为伴随现象,也可能代表胰岛素和葡萄糖输注的真实危害,目前尚不清楚。
要点
- 入住ICU>24 h患者中,静脉胰岛素每增加0.1 IU/kg与ICU病死率升高相关(OR 1.09,95%CI 1.05-1.13)。
- 同一人群中,静脉胰岛素每增加0.1 IU/kg与住院病死率升高相关(OR 1.09,95%CI 1.06-1.13)。
- 静脉葡萄糖每增加1 g/d与ICU病死率相关(OR 1.01,95%CI 1.00-1.01),与住院病死率无显著相关(OR 1.00,95%CI 1.00-1.01)。
- 入住>72 h亚组(n=1550)中,胰岛素剂量与ICU病死率(p=0.002)和住院病死率(p<0.001)相关,葡萄糖输注与两者均无显著相关(p=0.08和p=0.2)。
- 作者认为,该相关性可能是伴随现象,也可能代表真实危害,目前尚不明确。
适用人群与场景
- 2012年1月至2017年9月间一所内科-外科ICU收治的全部患者。
- 排除入住<24 h、糖尿病酮症酸中毒、入住时限制治疗及再入院的患者。
- 最终纳入3966例入住>24 h患者;其中1550例入住>72 h进行亚组分析。
研究设计与关键结果
- 研究类型:回顾性关联研究;样本量:9507例符合条件,最终纳入3966例;人群:内科-外科ICU患者。
- 主要分析(n=3966,入住>24 h):校正潜在混杂因素后,静脉胰岛素每增加0.1 IU/kg与ICU病死率相关(OR 1.09,95%CI 1.05-1.13),与住院病死率相关(OR 1.09,95%CI 1.06-1.13)。
- 静脉葡萄糖每增加1 g/d与ICU病死率相关(OR 1.01,95%CI 1.00-1.01),与住院病死率无显著相关(OR 1.00,95%CI 1.00-1.01)。
- 亚组分析(n=1550,入住>72 h):胰岛素剂量与ICU病死率相关(p=0.002),与住院病死率相关(p<0.001);葡萄糖输注与ICU病死率无显著相关(p=0.08),与住院病死率无显著相关(p=0.2)。
证据类型、等级与局限
- 证据类型:回顾性关联研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,静脉胰岛素给药与ICU及住院病死率升高风险相关;胃肠外葡萄糖给药量有限,但仍与ICU病死率相关;基于这些结果,尚不清楚该相关性是伴随现象还是胰岛素和葡萄糖给药的真实危害。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: We assessed the association of intravenous insulin and glucose infusion with intensive care unit (ICU) and hospital mortality.
METHODS: For this retrospective association study, we used data from all patients admitted to a medical-surgical ICU between January 2012 and September 2017. We excluded patients admitted < 24 h, patients with a diabetic ketoacidosis, patients with a therapy restriction upon ICU admission and readmissions. Using multivariate logistic regression, we examined the relation between intravenous insulin and glucose infusion and ICU and hospital mortality for all patients. Additionally, we used the same model to analyze the outcomes for patients admitted > 72 h.
RESULTS: Of 9507 eligible patients, 3966 were included. After correction for potential confounders, intravenous insulin was associated with ICU and hospital mortality in patients admitted > 24 h (n = 3966) (odds ratio (OR) 1.09 [95% CI 1.05-1.13] and 1.09 [95% CI 1.06-1.13] per 0.1 IU/kg added, respectively). Likewise, intravenous glucose was associated with ICU mortality (OR 1.01 [95% CI 1.00-1.01]) but not with hospital mortality and (OR 1.00 [95% CI 1.00-1.01]) per g/day added, respectively. In patients admitted > 72 h (n = 1550), insulin dose was associated with both ICU and hospital mortality (p = 0.002 and p < 0.001, respectively), but glucose infusion was not (p = 0.08 and p = 0.2, respectively).
CONCLUSIONS: Intravenous insulin administration is associated with an increased risk of ICU and hospital mortality, after correction for potential confounders. Parenteral glucose administration was limited in amount but was still associated with ICU mortality. However, based on these results, it is unknown whether this association is an epiphenomenon, or represents a true harm of insulin and glucose administration.
参考来源
- van Steen SC, Rijkenberg S, van der Voort PHJ, et al. The association of intravenous insulin and glucose infusion with intensive care unit and hospital mortality: a retrospective study. Ann Intensive Care. 2019. PMID: 30742240. doi:10.1186/s13613-019-0507-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。